Bayforest Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Bayforest Capital’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$181K	Buy	+15,429	New	+$252K	0.27%	70

Other funds holding MLTX

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Achmea Investment Management Zeist, Netherlands $12.6B AUM 25.68% 1-Year Est. Return

BankPlus Wealth Management Jackson, Mississippi $229M AUM 13.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Arizona State Retirement System Phoenix, Arizona $20.3B AUM 36.55% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Bayforest Capital's MLTX Position: Q3 2026 in Review

Bayforest Capital opened a new position in MoonLake Immunotherapeutics (MLTX) in Q3 2026: 15,429 shares worth $181K. The stake represents 0.27% of the portfolio and ranks #70 among its holdings.

28 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

Bayforest Capital held 15,429 shares of MoonLake Immunotherapeutics worth $181K as of Q3 2026.
MoonLake Immunotherapeutics was a new Bayforest Capital position in Q3 2026.
MoonLake Immunotherapeutics made up 0.27% of Bayforest Capital's portfolio in Q3 2026, its #70 holding.
28 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on Bayforest Capital's 13F filing for Q3 2026, filed 3 Nov 2026.